HUNT VALLEY, Md.,. March 17, 2011 /PRNewswire/ — Pharmaceutics
International Inc. (Pii), a leading contract development and
manufacturing organization, today announced the appointment of
Rampurna Prasad Gullapalli as vice president of Drug Delivery
Technologies. Dr. Gullapalli is responsible for providing
strategic scientific and technical leadership in areas of softgel,
liquid-filled hard capsules, and novel drug delivery technologies
for Pii’s contract development and manufacturing business.
“Prasad’s extensive background in oral dosage form development
adds to Pii’s leadership position as a foremost provider of oral
dosage form development and GMP manufacturing services to the
pharmaceutical industry,” said Steve King, senior vice president of
Pii. “We look forward to him helping us continually grow our oral
formulation development capabilities.”
Prior to joining Pii, Dr. Gullapalli served as an associate
director of Elan Pharmaceuticals, where he was responsible for
preformulation and oral dosage form development. He also served in
various scientific positions with increasing responsibilities at
Chiron Corporation, Purdue Pharma, Banner Pharmacaps and R.P.
Scherer (now Catalent). During his career, Dr. Gullapalli has
had extensive experience in the development and manufacturing of a
broad range of dosage forms including softgels, liquid-filled hard
capsules, nanosuspensions, suspensions, solutions, and controlled
release tablets and capsules for highly insoluble and soluble
compounds.
Dr. Gullapalli holds a Ph.D. in Pharmaceutics form the
University of Tennessee, Memphis and a Masters in Pharmacy in
Phamracology from Andhra University (India). He holds Regulatory
Affairs Certification (RAC-US) and is experienced in the FDA and
EMA CMC regulatory submissions. Dr. Gullapalli is an invited
guest lecturer at the University of California at Davis and
authored/co-authored several publications in professional journals
and pres
‘/>”/>
